IFNA2 and COVID-19: No difference in 60-day survival was found when comparing critical and severe COVID-19 patients who had neutralizing IFN-α2 Abs (n = 12) versus those who did not have (n = 150) neutralizing levels in univariate analysis (HR 1.90, 95% CI 0.56–6.40).